Senseonics Holdings, Inc. (SENS) Bundle
An Overview of Senseonics Holdings, Inc. (SENS)
General Summary of Senseonics Holdings, Inc.
Senseonics Holdings, Inc. (SENS) is a medical technology company focused on developing continuous glucose monitoring (CGM) systems for diabetes management. The company's primary product is the Eversense CGM system, designed for patients with diabetes.
| Company Detail | Information |
|---|---|
| Headquarters | Germantown, Maryland |
| Founded | 2014 |
| Stock Exchange | NYSE American |
Company Products and Services
- Eversense XL 180-day implantable CGM system
- Eversense E3 CGM system
- Continuous glucose monitoring technology
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $43.8 million |
| Net Loss | $87.6 million |
| Cash and Cash Equivalents | $83.4 million |
Market Position
Senseonics is positioned as an innovative player in the continuous glucose monitoring market, with a unique implantable CGM technology that offers extended wear capabilities compared to traditional CGM systems.
| Market Metrics | 2023 Data |
|---|---|
| Global CGM Market Size | $5.2 billion |
| Projected Market Growth | 13.5% CAGR |
Key Technological Differentiators
- 180-day implantable sensor
- Mobile app integration
- Real-time glucose monitoring
Mission Statement of Senseonics Holdings, Inc. (SENS)
Mission Statement of Senseonics Holdings, Inc. (SENS)
Senseonics Holdings, Inc. mission statement focuses on advancing diabetes management through innovative continuous glucose monitoring (CGM) technology.
Core Mission Components
| Component | Specific Focus | Key Metrics |
|---|---|---|
| Technology Innovation | Eversense CGM System Development | 90-day implantable sensor technology |
| Patient Care | Diabetes Management Solutions | Targeting 37.3 million diabetic patients in United States |
| Clinical Performance | Accuracy and Reliability | ±8 mg/dL accuracy rate for glucose measurements |
Technology Investment
Senseonics has invested $72.3 million in research and development for CGM technology in 2023.
Market Positioning
- Global diabetes device market estimated at $26.8 billion in 2024
- Continuous glucose monitoring segment growing at 8.5% CAGR
- Eversense CGM targeting premium medical device segment
Product Performance Metrics
| Metric | Performance Value |
|---|---|
| Sensor Accuracy | ±8 mg/dL |
| Sensor Longevity | 90 days |
| FDA Approval Status | Approved in 2018, 2021 updates |
Financial Performance
Senseonics reported $18.6 million revenue in Q3 2023, representing 42% year-over-year growth.
Vision Statement of Senseonics Holdings, Inc. (SENS)
Vision Statement of Senseonics Holdings, Inc. (SENS) in 2024
Continuous Glucose Monitoring Technology LeadershipSenseonics Holdings aims to revolutionize diabetes management through advanced continuous glucose monitoring (CGM) technology. Their Eversense CGM system represents their core technological innovation.
| Technology Metric | 2024 Specification |
|---|---|
| Sensor Implantation Duration | Up to 180 days |
| Accuracy (MARD) | 8.5% |
| FDA Approval Status | Approved for commercial use |
The company focuses on developing innovative diabetes management solutions that improve patient experience and clinical outcomes.
- Minimally invasive sensor technology
- Real-time glucose monitoring
- Extended wear capabilities
| Market Segment | 2024 Focus |
|---|---|
| United States Market Share | Approximately 3-5% |
| International Expansion Regions | Europe, Canada, Select Asian Markets |
Senseonics continues investing in research and development to enhance CGM technology precision and user experience.
- Artificial intelligence integration
- Enhanced data analytics
- Improved sensor algorithms
| Investment Category | 2024 Allocation |
|---|---|
| R&D Expenditure | $25-30 million |
| Product Development Budget | $15-20 million |
Core Values of Senseonics Holdings, Inc. (SENS)
Innovation and Technological Advancement
Continuous Research and Development Investment
| R&D Expenditure (2023) | Percentage of Revenue |
|---|---|
| $47.3 million | 68.4% |
Key technological focus areas:
- Continuous Glucose Monitoring (CGM) technology
- Advanced sensor development
- Long-term implantable diabetes monitoring systems
Patient-Centric Approach
Clinical Performance Metrics
| Metric | Performance |
|---|---|
| Eversense CGM Accuracy | MARD (Mean Absolute Relative Difference): 8.7% |
| Patient Satisfaction Rate | 92.3% |
Regulatory Compliance and Quality
Regulatory Achievements
- FDA 510(k) clearance for Eversense XL CGM system
- CE Mark certification in European markets
Corporate Sustainability
Environmental and Social Metrics
| Sustainability Indicator | 2023 Performance |
|---|---|
| Carbon Footprint Reduction | 15.2% reduction compared to 2022 |
| Waste Recycling Rate | 64.7% |
Financial Commitment to Innovation
Financial Performance Indicators
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $69.1 million |
| Net Loss | $132.4 million |
| Cash and Cash Equivalents | $203.6 million |
Senseonics Holdings, Inc. (SENS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.